Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$15.07 +0.5%	$15.09	$8.89 ▼ $24.50	$653.38M	N/A	515,639 shs	1.05 million shs
INMD InMode	$14.19 +0.9%	$14.40	$13.14 ▼ $19.85	$896.94M	1.98	1.22 million shs	12.96 million shs
MDXG MiMedx Group	$5.94	$6.55	$5.47 ▼ $10.14	$877.35M	1.83	673,314 shs	1.99 million shs
SMTI Sanara MedTech	$28.41 +0.2%	$30.23	$25.86 ▼ $39.08	$252.50M	1.36	27,739 shs	104,676 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	0.00%	-15.76%	-1.89%	+28.69%	+1,506,999,900.00%
INMD InMode	0.00%	+6.85%	-2.74%	-19.83%	-18.02%
MDXG MiMedx Group	0.00%	+2.24%	-9.31%	-21.22%	-10.94%
SMTI Sanara MedTech	0.00%	+4.14%	-3.07%	-5.90%	+1.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INMD InMode	3.6762 of 5 stars	4.1	3.0	0.0	0.0	1.9	1.7	1.9
MDXG MiMedx Group	3.557 of 5 stars	3.5	3.0	0.0	0.0	2.6	3.3	1.3
SMTI Sanara MedTech	2.2067 of 5 stars	3.5	1.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$23.44	55.57% Upside
INMD InMode	2.13	Hold	$18.54	30.67% Upside
MDXG MiMedx Group	3.00	Buy	$12.50	110.44% Upside
SMTI Sanara MedTech	3.00	Buy	$49.50	74.23% Upside

Current Analyst Ratings Breakdown

Latest SMTI, MDXG, INMD, and BBNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/15/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $53.00
4/30/2025	INMD InMode	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $24.00
4/29/2025	INMD InMode	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$19.00 ➝ $16.25
4/29/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $15.00
4/29/2025	INMD InMode	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/28/2025	INMD InMode	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	INMD InMode	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$22.00 ➝ $16.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$65.12M	10.03	N/A	N/A	($5.72) per share	-2.63
INMD InMode	$394.82M	2.27	$1.82 per share	7.78	$10.12 per share	1.40
MDXG MiMedx Group	$348.88M	2.51	$0.33 per share	17.93	$1.31 per share	4.53
SMTI Sanara MedTech	$86.67M	2.91	N/A	N/A	$4.45 per share	6.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INMD InMode	$181.27M	$2.33	6.09	7.80	N/A	44.79%	17.17%	15.20%	7/30/2025 (Estimated)
MDXG MiMedx Group	$42.42M	$0.27	22.00	18.56	N/A	11.40%	22.70%	16.77%	7/30/2025 (Estimated)
SMTI Sanara MedTech	-$9.66M	-$1.34	N/A	N/A	N/A	-12.48%	-29.22%	-13.20%	8/11/2025 (Estimated)

Latest SMTI, MDXG, INMD, and BBNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SMTI Sanara MedTech	-$0.31	-$0.41	-$0.10	-$0.41	$23.48 million	$23.43 million
5/6/2025	Q1 2025	BBNX Beta Bionics	-$0.51	-$0.52	-$0.01	-$0.93	N/A	N/A
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	15.88	14.93
INMD InMode	N/A	8.73	7.86
MDXG MiMedx Group	0.09	4.70	4.13
SMTI Sanara MedTech	1.18	2.77	2.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
INMD InMode	68.04%
MDXG MiMedx Group	79.15%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
INMD InMode	6.92%
MDXG MiMedx Group	1.70%
SMTI Sanara MedTech	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.36 million	N/A	N/A
INMD InMode	480	63.21 million	58.84 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.19 million	Optionable
SMTI Sanara MedTech	60	8.89 million	5.10 million	Not Optionable

SMTI, MDXG, INMD, and BBNX Headlines

Recent News About These Companies

Cantor Fitzgerald Estimates Sanara MedTech FY2026 Earnings

June 11, 2025 | marketbeat.com

Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

June 9, 2025 | seekingalpha.com

Sanara MedTech Inc. (NASDAQ:SMTI) Short Interest Down 13.7% in May

June 5, 2025 | marketbeat.com

Sanara MedTech Shares Down, Investors Sought For Pilot Program

May 15, 2025 | marketwatch.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | gurufocus.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock News

May 14, 2025 | gurufocus.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | investing.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | globenewswire.com

With 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's future

May 6, 2025 | uk.finance.yahoo.com

Sanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025

April 23, 2025 | quiverquant.comQ

Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025

April 23, 2025 | globenewswire.com

Sanara MedTech to Present at Investor Showcase

April 22, 2025 | tipranks.com

Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

April 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI, MDXG, INMD, and BBNX Company Descriptions

Beta Bionics NASDAQ:BBNX

$15.07 +0.08 (+0.53%)

As of 06/27/2025 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

InMode NASDAQ:INMD

$14.19 +0.12 (+0.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$14.19 0.00 (0.00%)

As of 06/27/2025 07:57 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group NASDAQ:MDXG

$5.94 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.94 +0.00 (+0.08%)

As of 06/27/2025 04:34 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Sanara MedTech NASDAQ:SMTI

$28.41 +0.05 (+0.18%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$28.42 +0.01 (+0.04%)

As of 06/27/2025 07:57 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time